Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 37822681

Next Previous
X
Search
Drug Profile

JNJ 37822681

Alternative Names: JNJ-37822681

Latest Information Update: 18 Aug 2015

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 18 Aug 2015 No recent reports on development identified - Phase-II for Schizophrenia in Slovakia, Bulgaria, Germany, Ukraine, Russia, Romania, Lithuania, Estonia, India, Taiwan, South Korea, Sweden, Belgium, South Africa and Malaysia (PO)
  • 16 Sep 2009 Pharmacodynamics and adverse events data from a phase I trial in Schizophrenia presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP-2009)
  • 11 Aug 2008 Preclinical trials in Schizophrenia in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top